<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025285</url>
  </required_header>
  <id_info>
    <org_study_id>REBACDR0000068946</org_study_id>
    <secondary_id>CCCWFU-62400</secondary_id>
    <secondary_id>NCI-5293</secondary_id>
    <nct_id>NCT00025285</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Study of Carboplatin, Irinotecan, and Thalidomide in Patients With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <brief_summary>
    <textblock>
      RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.&#xD;
      Combining thalidomide with chemotherapy may kill more tumor cells and be an effective&#xD;
      treatment for stage IIIB or stage IV non-small cell lung cancer.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus&#xD;
      thalidomide in treating patients who have stage IIIB or stage IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate and duration of response in patients with stage IIIB or IV&#xD;
           non-small cell lung cancer treated with carboplatin, irinotecan, and thalidomide.&#xD;
&#xD;
        -  Determine the progression-free and overall survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Evaluate the toxicity profile of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive carboplatin IV over 30 minutes on day 1 and irinotecan IV over 90&#xD;
      minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression&#xD;
      or unacceptable toxicity. Patients with stable or responsive disease receive up to 6 courses&#xD;
      of therapy. Patients also receive oral thalidomide once daily beginning on day 1 and&#xD;
      continuing until disease progression.&#xD;
&#xD;
      Patients are followed every 3 months until disease progression and then every 6 months&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 39-70 patients will be accrued for this study within 14 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2001</start_date>
  <completion_date type="Actual">September 29, 2004</completion_date>
  <primary_completion_date type="Actual">September 29, 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">46</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed stage IIIB (malignant pleural effusion) or&#xD;
             stage IV non-small cell lung cancer&#xD;
&#xD;
               -  Squamous cell carcinoma&#xD;
&#xD;
               -  Basaloid carcinoma&#xD;
&#xD;
               -  Adenocarcinoma&#xD;
&#xD;
               -  Bronchoalveolar carcinoma&#xD;
&#xD;
               -  Adenosquamous carcinoma&#xD;
&#xD;
               -  Large cell carcinoma&#xD;
&#xD;
               -  Large cell neuroendocrine carcinoma&#xD;
&#xD;
               -  Giant cell carcinoma&#xD;
&#xD;
               -  Sarcomatoid carcinoma&#xD;
&#xD;
               -  Non-small cell carcinoma not otherwise specified&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion&#xD;
&#xD;
                    -  At least 20 mm by conventional techniques OR&#xD;
&#xD;
                    -  At least 10 mm by spiral CT scan&#xD;
&#xD;
               -  The following lesions are considered nonmeasurable:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural or pericardial effusions&#xD;
&#xD;
                    -  Abdominal masses unconfirmed by imaging techniques&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
                    -  Previously irradiated brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 2 methods of effective contraception 4 weeks prior to,&#xD;
             during, and for at least 4 weeks after thalidomide&#xD;
&#xD;
          -  No prior seizures&#xD;
&#xD;
          -  No other concurrent or prior malignancy within the past 5 years except inactive&#xD;
             nonmelanoma skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other serious medical or psychiatric illness that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal therapy except steroids for adrenal failure, hormones for&#xD;
             non-cancer-related conditions (e.g., insulin for diabetes) or intermittent&#xD;
             dexamethasone as an antiemetic&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Prior radiotherapy for brain metastasis allowed if neurologically stable and off&#xD;
             steroids&#xD;
&#xD;
          -  No concurrent palliative radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonius A. Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James N. Atkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southeastern Medical Oncology Center - Goldsboro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Central Illinois</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534-9479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>adenosquamous cell lung cancer</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

